Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.

Remarkable improvements in outcomes for many haematological malignancies have been driven primarily by a proliferation of novel therapeutics over the past ...

Remarkable improvements in outcomes for many haematological malignancies have been driven primarily by a proliferation of novel therapeutics over the past ...

May 1, 2023 · Remarkable improvements in outcomes for many hematologic malignancies have been driven primarily by a proliferation of novel therapeutics ...

Adverse event burden score—a versatile summary measure for cancer clinical trials. Cancers (Basel). 2020; 123251. View in Article. Scopus (19) · PubMed ...

This review provides a summary of the unique toxicity profiles of therapies for hematologic malignancies during the last decade with a focus on clinical ...

May 6, 2022 · Remarkable improvements in outcomes for many haematological malignancies have been driven primarily by a proliferation of novel therapeutics ...

Jun 12, 2018 · Panel 2: Immune-related adverse events: a new context of adverse event assessment in haematological malignancies. Advances in immunotherapy, ...

Adverse Event 100% · Hematologic Malignancy 100% · Cell Therapy 40% · Clinician 20% · Malignant Neoplasm 20% · Survivorship in Cancer Care 20% · Immunotherapy 20%.

Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.